Table 1.
The clinical parameters of the study population.
| Variables | Groups of cycles according to the tertiles of HOMA-IR | P value1 | ||
|---|---|---|---|---|
| T1 (< 2.32) | T2 (2.32 - 3.87) | T3 (> 3.87) | ||
| Number | 503 | 502 | 503 | |
| Age (y) | 29.44 ± 3.55 | 28.87 ± 3.53 | 28.59 ± 3.82 | <0.001 |
| BMI (kg/m2) | 22.77 ± 2.76 | 25.03 ± 3.38 | 27.95 ± 3.56 | <0.001 |
| AMH (ng/ml) | 7.61 (5.29-10.89) | 7.30 (5.07-10.44) | 6.75 (4.31-9.65) | <0.001 |
| Basal FSH (mIU/ml) | 5.93 ± 1.41 | 5.76 ± 1.50 | 5.48 ± 1.43 | <0.001 |
| Basal LH (mIU/ml) | 8.44 (5.66-13.38) | 7.75 (5.02-11.92) | 7.29 (4.50-10.54) | <0.001 |
| AFC | 22.75 ± 3.72 | 23.17 ± 3.54 | 23.97 ± 3.86 | <0.001 |
| FG (mmol/l) | 4.63 ± 0.47 | 4.84 ± 0.48 | 5.07 ± 0.54 | <0.001 |
| FINS (μU/ml) | 8.05 ± 2.15 | 14.17 ± 2.40 | 27.59 ± 10.67 | <0.001 |
| HOMAIR | 1.72 (1.37-1.99) | 3.00 (2.61-3.41) | 5.38 (4.50-7.00) | <0.001 |
| COS protocol | 0.034 | |||
| GnRH agonist | 406 (80.72%) | 427 (85.06%) | 435 (86.48%) | |
| GnRH antagonist | 97 (19.28%) | 75 (14.94%) | 68 (13.52%) | |
| Initial Gn dose (IU) | 128.88 ± 31.38 | 135.21 ± 28.54 | 147.69 ± 36.24 | <0.001 |
| Total Gn dose (IU) | 1826.78 ± 875.73 | 2183.34 ± 1168.43 | 2730.55 ± 1218.45 | <0.001 |
| Duration of Gn (d) | 11.22 ± 3.10 | 12.07 ± 3.56 | 13.15 ± 3.51 | <0.001 |
| Dominant follicle count on trigger day | 9.87 ± 4.68 | 9.54 ± 4.84 | 9.09 ± 4.49 | 0.028 |
| Retrieved oocytes | 14.00 (10.00-20.00) | 13.00 (8.00-18.00) | 12.00 (8.00-17.50) | <0.001 |
| MII oocytes | 12.00 (8.00-16.00) | 11.00 (7.00-16.00) | 10.00 (7.00-15.00) | <0.001 |
| Embryos count | 7.00 (4.00-10.00) | 6.00 (3.00-10.00) | 5.00 (3.00-9.00) | 0.003 |
| Endometrium on ET day (mm) | 10.82 ± 2.45 | 11.06 ± 2.42 | 11.00 ± 2.72 | 0.619 |
| OSI | 8.37 (5.14-13.33) | 6.40 (3.88-10.79) | 4.57 (2.85-7.23) | <0.001 |
BMI, Body Mass Index; AMH, anti-mullerian hormone; FSH, follicle stimulating hormone; LH, luteinizing hormone; AFC, antral follicle count; HOMA-IR, homeostatic model assessment of insulin resistance; FG, fasting glucose; FINS, fasting serum insulin; COS, controlled ovarian stimulation; GnRH, gonadotropin releasing hormone; Gn, gonadotropin; OSI, ovarian sensitivity index; MII, metaphase II; ET, embryo transfer; A two-tailed P value < 0.05 was considered statistically significant.